Allopurinol

• DALY II USA/MB-CART2019.1 for DLBCL Pending
  2023-508508-39-01 Phase II 2 countries Miltenyi Biomedicine GmbH
• Stop Treatment in gout Pending
  2024-515714-40-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• Phase 3 Study of Dotinurad vs Allopurinol in Participants With Gout Recruiting
  2024-520206-19-00 Phase III 2 countries Crystalys Therapeutics Inc.
• Trial of an investigational drug after the rejection of an allogeneic transplant. Recruiting
  2022-503063-15-00 Phase I (FiH) 1 country Fundacion Publica Andaluza para la Gestion de la Investigacion en Salud de Sevil…
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting
  2023-505436-35-00 Phase III 6 countries Lysarc
• Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy Recruiting
  2024-513601-31-00 Phase II 1 country Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…
• Allopurinol as a preventive drug in patients with high and very high cardiovascular risk, taking into account the presence of the long-COVID… Recruiting
  2024-517610-15-00 Phase III 1 country Uniwersytet Medyczny Im. Karola Marcinkowskiego W Poznaniu
• First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-… Recruiting
  2023-510431-11-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• Trial evaluating the safety and efficacy of Venetoclax in addition to a standard conditioning regime in patients with certain forms of leuke… Recruiting
  2024-514688-24-00 Phase I/II 1 country Heinrich-Heine-Universitaet Duesseldorf
• Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended
  2024-511627-34-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to expre… Ended
  2024-515467-66-00 Phase II 1 country Fundacio Sant Joan De Deu
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended
  2023-506986-74-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
• A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML Ended
  2024-514356-33-00 Phase I (FiH) 3 countries Institut De Recherches Internationales Servier IRIS
• GO TEST FINALE Ended
  2024-511111-13-01 Phase IV 1 country Sint Maartenskliniek
• A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi… Ended
  2022-501421-20-00 Phase III 9 countries LG Chem Ltd.

Showing 1–15 of 15 trials